Global Anti-Epilepsy Drugs Market Forecast 2017-2027

抗てんかん薬の世界市場予測

◆タイトル:Global Anti-Epilepsy Drugs Market Forecast 2017-2027
◆商品コード:VGAIN705040
◆調査・発行会社:visiongain
◆発行日:2017年5月
◆ページ数:145
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、抗てんかん薬の世界市場について調査・分析し、抗てんかん薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・抗てんかん薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・抗てんかん薬の世界市場:セグメント別市場分析
・抗てんかん薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 145-page report you will receive 100 charts – all unavailable elsewhere.

The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Epilepsy Drugs Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
- First-generation Drugs
- Second-generation Drugs
- Third-generation Drugs
- Others

• This report also discusses the leading anti-epilepsy drugs:
- Vimpat
- Keppra
- Briviact
- Lamictal
- Potiga/Trobalt
- Lyrica
- Neurontin

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
- US
- Japan
- EU5
- BRIC
- RoW

• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK

• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market

• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy

• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market

• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.

Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Epilepsy
2.1 What are Seizures?
2.2 What is status epilepticus?
2.2.1 Types of Seizures
2.2.1.1 Onset of Seizures
2.2.1.2 Level of Awareness
2.2.1.3 Presence or Absence of Motor Symptoms
2.3 Epilepsy Syndrome
2.4 What Are the Risk Factors for Epilepsy?
2.4.1 Age
2.4.2 Head injuries
2.4.3 Family History
2.4.4 Childhood Seizures
2.4.5 Infections
2.4.6 Dementia and Vascular Diseases
2.4.7 Administration of Drugs
2.5 What Are the Various Complications Associated with Epilepsy?
2.5.1 Increased Likelihood of Road Accidents
2.5.2 Increased Risk of Falls and Drowning while Swimming
2.5.3 Complications during Pregnancy
2.5.4 Impairment of Mental Health and Social Stigma Associated with the Disease
2.5.5 Status Epilepticus
2.5.6 Sudden Unexplained Death in Epilepsy (SUDEP)
2.6 Diagnosis of Epilepsy
2.6.1.1 Electroencephalogram (EEG)
2.6.1.2 Neuroimaging
2.6.1.3 Other Tests
2.6.1.4 Neuropsychological Assessment
2.7 Epidemiology of Epilepsy
2.7.1 Incidence
2.7.2 Prevalence
2.7.2.1 Epidemiology by Country
2.7.2.2 Historical Prevalence in G7 Markets
2.7.2.3 Forecast of Epilepsy in G7 Markets 2016-2027
2.8 Humanistic and Economic Burden
2.8.1 Mortality
2.8.1.1 Mortality in the US
2.8.1.2 Mortality in the UK
2.8.2 HRQoL
2.8.3 Economic Impact
2.8.3.1 Direct and Indirect Costs of Caregiving
2.9 Epilepsy: Treatment
2.9.1 Pharmacotherapy
2.9.2 Psychological Interventions
2.9.3 Dietary Modifications
2.9.4 Vagus Nerve Stimulation (VNS)
2.9.5 Epilepsy Surgery
2.9.6 Deep Brain Stimulation (DBS)
2.9.7 Responsive Neurostimulation System (RNS)

3. Introduction to the Anti-Epilepsy Drugs Market
3.1 Market Definition and Scope
3.2 Market Drivers, Challenges, and Trends
3.2.1 Market Drivers
3.2.1.1 Unmet Medical Need
3.2.1.2 Increase in Patient Population
3.2.1.3 Research Funding and Awareness
3.2.2 Market Challenges
3.2.2.1 Market Entry of Generic Drugs
3.2.2.2 Social Stigma Associated with Neurological Disorders
3.2.3 Market Trends
3.2.3.1 Reformulation and Indication Expansion
3.2.3.2 Emergence of New-generation of AEDs

4. Global Anti-Epilepsy Drugs Market 2016
4.1 Global Anti-Epilepsy Drugs Market Forecast 2017-2027
4.1 Market Segmentation by Generation of Drugs
4.1.1 Global Anti-Epilepsy Drugs Submarkets Forecast 2017-2027
4.1.1.1 Global Anti-Epilepsy First Generation Drugs Market Forecast 2017-2027
4.1.1.2 Global Anti-Epilepsy Second Generation Drugs Market Forecast 2017-2027
4.1.1.3 Global Anti-Epilepsy Third Generation Drugs Market Forecast 2017-2027
4.1.1.4 Global Anti-Epilepsy Other Drugs Market Forecast 2017-2027

5. Global Anti-Epilepsy Drugs – Market Players
5.1 Historical Market Share
5.2 Current Market Leaders
5.2.1 UCB
5.2.1.1 Vimpat
5.2.1.2 Keppra
5.2.1.3 Briviact
5.2.2 GlaxoSmithKline
5.2.2.1 Lamictal
5.2.2.2 Potiga / Trobalt
5.2.3 Pfizer
5.2.3.1 Lyrica
5.2.3.2 Neurontin

6. Leading National Markets Forecast 2017-2027
6.1 Geographical Breakdown of Global Anti-Epilepsy Drugs Market, 2016
6.2 Anti-Epilepsy Drugs Market Forecast by Region 2017-2027
6.3 Anti-Epilepsy Drugs Market in the US, 2016
6.3.1 Market Forecast of the US, 2017-2027
6.4 Anti-Epilepsy Drugs Market in EU5, 2016
6.4.1 Market Forecast of EU5, 2017-2027
6.5 Anti-Epilepsy Drugs Market in the BRIC, 2016
6.5.1 Market Forecast of the BRIC, 2017-2027
6.6 Anti-Epilepsy Drugs Market in Japan, 2016
6.6.1 Market Forecast of the Japan, 2017-2027
6.7 Anti-Epilepsy Drugs Market in RoW, 2016
6.7.1 Market Forecast of the RoW, 2017-2027

7. Pricing and Reimbursement Overview
7.1 NICE
7.2 SMC
7.3 HAS
7.4 Canada
7.5 Italy
7.6 United States
7.7 Australia
7.8 G-BA/IQWIG

8. Active Pipeline Molecules
8.1 Overall Pipeline Status and Promising Candidates
8.1.1 Everolimus
8.1.2 Lyrica Controlled-release
8.1.3 Briviact
8.1.4 Vimpat
8.1.5 E2007
8.1.6 SAGE-547
8.1.7 Epidiolex
8.1.8 Cenobamate
8.1.9 ZX008
8.1.10 Ganaxolone
8.1.11 Immunoglobulin, normal (human)
8.1.12 USL261
8.1.13 Alprazolam
8.1.14 Ataluren
8.1.15 GWP42006
8.1.16 PF-062372865
8.1.17 UCB-0942 and UCB-3491
8.1.18 BGG-492
8.1.19 PRX00023
8.2 Novel Mechanism of Action

9. Conclusions

Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Tables
Table 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Forecast 2017-2027 ($m, AGR %, Cumulative)
Table 2.1 Type of Focal Seizures
Table 2.2 Type of Unknown-onset Seizures
Table 2.3 Prevalence of Epilepsy, all ages, all types, rates per 1,000 population per year
Table 2.4 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
Table 2.5 Forecast of Diagnosed Prevalence of Epilepsy in G7 Markets: AGR (%), CAGR (%), 2016-2027
Table 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
Table 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
Table 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
Table 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
Table 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
Table 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
Table 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
Table 2.13 Healthcare Utilization Rates by Caregivers of Individuals Suffering from Epilepsy vs General Population
Table 2.14 Direct and Indirect Costs for the General Population and Caregivers of Persons with Epilepsy (in US$)
Table 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.2 List of some of the Approved AEDs
Table 4.3 Global Anti-Epilepsy Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2016
Table 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.5 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
Table 4.6 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.7 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.8 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.9 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.1 Product Portfolio of UCB
Table 5.2 Vimpat Key Milestones
Table 5.3 Keppra / Keppra XR Key Milestones
Table 5.4 Briviact Key Milestones
Table 5.5 Product Portfolio of Pfizer
Table 6.1 Anti-Epilepsy Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 6.2 Anti-Epilepsy Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027
Table 6.3 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.4 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.5 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.6 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.7 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 8.1 Active Pipeline Molecules under Development for Treating Epilepsy

List of Figures
Figure 1.1 Example of Global Anti-Epilepsy Drugs Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.1 Types of Generalized Seizures
Figure 2.2 Diagnosed Prevalence (absolute cases) of Epilepsy in G7 Markets, 2016
Figure 2.3 Diagnosed Prevalence (%) of Epilepsy in G7 Markets, 2016
Figure 2. 4 Historical Prevalence of Epilepsy in G7 Markets: CAGR (%), 2011-2015
Figure 2.5. Historical Diagnosed Prevalence of Epilepsy in G7 Markets: Share (%) of Absolute cases, 2011-2015
Figure 2.6 Forecast of Diagnosed Prevalence of Epilepsy in the US: AGR (%), CAGR (%), 2016-2027
Figure 2.7 Forecast of Diagnosed Prevalence of Epilepsy in France: AGR (%), CAGR (%), 2016-2027
Figure 2.8 Forecast of Diagnosed Prevalence of Epilepsy in Germany: AGR (%), CAGR (%), 2016-2027
Figure 2.9 Forecast of Diagnosed Prevalence of Epilepsy in the UK: AGR (%), CAGR (%), 2016-2027
Figure 2.10 Forecast of Diagnosed Prevalence of Epilepsy in Italy: AGR (%), CAGR (%), 2016-2027
Figure 2.11 Forecast of Diagnosed Prevalence of Epilepsy in Spain: AGR (%), CAGR (%), 2016-2027
Figure 2.12 Forecast of Diagnosed Prevalence of Epilepsy in Japan: AGR (%), CAGR (%), 2016-2027
Figure 2.13 Epilepsy and Status Epilepticus Related Deaths in the US, 2015
Figure 2.14 Epilepsy and Status Epilepticus Related Deaths in the US, 2013 – 2015
Figure 2.15 Epilepsy and Status Epilepticus Related Deaths in the UK, 2015
Figure 2.16 Epilepsy Related Deaths in the UK, 2013 – 2015
Figure 2.17 Percentage of Adults with and Without Epilepsy Who Have Difficulty Getting Health Care
Figure 2.18Treatment Algorithm of Epilepsy using Pharmacotherapies
Figure 2.19 Pharmacotherapy for Seizures
Figure 2.20Treatment Algorithm of Status Epilepticus using Pharmacotherapies
Figure 4.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.2: Epilepsy Market Segmentation by Generation of Drugs
Figure 4.3 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), 2016
Figure 4.4 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Market Share (%), 2016
Figure 4.5 Global Anti-Epilepsy Drugs Market by Generation of Drugs 2016-2027: Revenue ($m), Global AGR (%)
Figure 4.6 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs: Revenue ($m), CAGR (%), 2016 & 2027
Figure 4.7 Global Anti-Epilepsy Drugs Market Segmentation by Generation of Drugs 2016-2027: AGR (%)
Figure 4.8 Global Anti-Epilepsy First Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.9 Global Anti-Epilepsy Second Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.10 Global Anti-Epilepsy Third Generation Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.11 Global Anti-Epilepsy Other Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 5.1 Market Share of AEDs, in 2008
Figure 5.2 Vimpat Revenue 2011-2016 (US$ million)
Figure 5.3 Vimpat Sales by Geographical Segmentation, 2016
Figure 5.4 Vimpat Forecasted Revenue 2017-2022 (US$ million)
Figure 5.5 Market Growth of Vimpat in the US and EU (in 2016)
Figure 5.6 Keppra/Keppra XR Revenue 2011-2016 (US$ million)
Figure 5.7 Keppra/Keppra XR Sales by Geographical Segmentation 2016
Figure 5.8 Keppra/Keppra XR Forecasted Revenue 2017-2022 (US$ million)
Figure 5.9 Market Growth of Keppra/Keppra XR in the US and EU (in 2016)
Figure 5.10 Briviact Sales by Geographical Segmentation 2016
Figure 5.11 Briviact Forecasted Revenue 2017-2022 (US$ million)
Figure 5.12 Lamictal Revenue 2011-2016 (US$ million)
Figure 5.13 Lamictal Sales by Geographical Segmentation 2016
Figure 5.14 Lyrica Revenue 2011-2016 (US$ million)
Figure 5.15 Neurontin Revenue 2011-2016 (US$ million)
Figure 6.1 Anti-Epilepsy Drugs Market Segmentation by Region/Country
Figure 6.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)
Figure 6.3 Anti-Epilepsy Drugs Market by Region: Market Share 2016 (%)
Figure 6.4 Global Anti-Epilepsy Drugs Market in the US: Market Share (%), 2016
Figure 6.5 Anti-Epilepsy Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)
Figure 6.6 Anti-Epilepsy Drugs Market in the EU5: Market Share (%), 2016
Figure 6.7 Anti-Epilepsy Drugs Market Forecast in EU5 2016-2027: Revenue ($m), AGR (%)
Figure 6.8 Anti-Epilepsy Drugs Market in BRIC: Market Share (%), 2016
Figure 6.9 Anti-Epilepsy Drugs Market Forecast in BRIC 2016-2027: Revenue ($m), AGR (%)
Figure 6.10 Anti-Epilepsy Drugs Market in Japan: Market Share (%), 2016
Figure 6.11 Anti-Epilepsy Drugs Market Forecast in Japan 2016-2027: Revenue ($m), AGR (%)
Figure 6.12 Anti-Epilepsy Drugs Market Forecast in RoW 2016-2027: Revenue ($m), AGR (%)
Figure 8.1 Share of Pipeline Molecules by Phase of Development
Figure 8.2 Status of Patent Protection of Afinitor (excludes patent on cancer indications
Figure 9.1 Global Anti-Epilepsy Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 9.2 Anti-Epilepsy Drugs Market by Region: Revenue ($m)

【レポートのキーワード】

抗てんかん薬、てんかん治療、医薬品

★調査レポート[抗てんかん薬の世界市場予測] ( Global Anti-Epilepsy Drugs Market Forecast 2017-2027 / VGAIN705040) 販売に関する免責事項
[抗てんかん薬の世界市場予測] ( Global Anti-Epilepsy Drugs Market Forecast 2017-2027 / VGAIN705040) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆